Compass Pathways' large clinical trial is testing whether a synthetic psilocybin pill can treat depression, and it's expected to hit its main goal — showing the drug works better than a placebo. The trial is nearly finished, the treatment already got a special 'promising' flag from the FDA, and earlier smaller studies showed positive results. If it succeeds, it's a major milestone for turning a psychedelic into a legitimate medicine.
The trial is ~86% complete with a breakthrough designation and prior supportive Phase 2 data, making statistical success on the primary endpoint the modal outcome even before regulatory interpretation.